Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Nilotinib | Tasigna